We found successful treatment in patients with AIP/IgG4-RD was associated with a significant reduction in serum concentrations of CXCL9, CXCL10, and CCL25 (Figure 11B). This evidence concerns the gene CXCL9 and immunoglobulin G4-related sclerosing disease.